Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2026-02-05 Major Shareholding Noti…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and specifically mentions '특별관계자의 주식담보대출 계약' (Special related party's stock collateral loan agreement). This type of filing is used to notify the market of significant changes in shareholding or collateralization by major shareholders. In the provided classification schema, this falls under 'Major Shareholding Notification' (MRQ).
2026-02-05 Korean
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is a formal announcement regarding an upcoming 'Corporate Presentation' (IR) event, specifically a Non-Deal Roadshow (NDR) scheduled for February 2026. It provides details such as date, location, purpose, and contact information. Since it is an announcement of an event rather than the presentation slides themselves, and it does not fit into specific categories like 'Investor Presentation' (which would be the slides) or 'Earnings Release', it is classified as a general regulatory announcement regarding corporate activities.
2026-01-23 Korean
[기재정정]증권발행결과(자율공시)
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from ABL Bio regarding the results of a securities issuance (specifically a third-party paid-in capital increase). It details the number of shares issued, the amount raised, and includes a correction notice regarding the expected listing date of the new shares. This falls under the category of share issuance and capital changes.
2026-01-16 Korean
[기재정정]주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed with the Korea Exchange (KRX). It details the specifics of a third-party capital increase, including share counts, pricing, and the purpose of the funds. This falls under the category of capital structure changes and financing activities.
2026-01-16 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed by ABL Bio. It details the correction of a previously filed report (정정신고) due to changes in exchange rates and administrative conditions. This document falls under the category of capital structure changes and financing activities, specifically a share issuance/capital change announcement.
2026-01-09 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a third-party allocated capital increase). It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2026-01-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.